# Apnimed

**Canonical:** https://apis.io/providers/apnimed/  
**Website:** https://apnimed.com/  
**APIs profiled:** 0

Apnimed is a late-stage clinical-stage pharmaceutical company headquartered in Cambridge, Massachusetts, developing novel oral drug therapies for sleep-related breathing disorders. Its lead candidate AD109 (Oxnimbi) is a fixed-dose combination of an anti-muscarinic and a selective norepinephrine reuptake inhibitor, designed to improve upper-airway muscle activity and treat an underlying neuromuscular cause of obstructive sleep apnea (OSA) rather than manage it mechanically. The company was founded in 2017, partners with Shionogi through the Shionogi-Apnimed Sleep Science (SASS) joint venture, and had a New Drug Application for AD109 accepted by the FDA in 2026. Apnimed is a drug developer, not a software vendor: it publishes no developer portal, API documentation, or machine-readable API artifacts.

## Kin Score — 12.2 / 100 (minimal)

Scored 2026-08-17 under rubric 0.11.0. Trend: flat (+0.0 from 12.2).

| Facet | Score |
|---|---|
| Discoverability | 57.4 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 6.5 |
| Commercial Clarity | 21.1 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Security (1)

- **Apnimed Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Pharmaceuticals, Biotechnology, Health Care, Life Sciences, Sleep Medicine, Clinical Trials

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/apnimed/). Scores are computed from the provider's own public artifacts under a published rubric.